Key points are not available for this paper at this time.
// Yaru Zou 1, * , Jianjing Tong 2, * , Haiyan Leng 3 , Jingwei Jiang 4 , Meng Pan 1, * and Zi Chen 5, 3, * 1 Department of Dermatology, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China 2 Exclusive Medical Care Center, Rui Jin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China 3 Department of Hematology, Huashan Hospital, Fudan University, Shanghai 200040, China 4 Department of Oncology, Huashan Hospital, Fudan University, Shanghai 200040, China 5 Quintiles Asia Medical Oncology, Shanghai 200032, China * These authors contributed equally to this work Correspondence to: Zi Chen, email: drchenzi2@163.com.cn Meng Pan, email: panmeng@medmail.com.cn Keywords: 18 F-fluorodeoxyglucose, positron emission tomography, positron emission tomography/computed tomography, primary central nervous system lymphoma, diagnosis Received: November 02, 2016 Accepted: April 12, 2017 Published: April 27, 2017 ABSTRACT Background: 18 F-fluorodeoxyglucose ( 18 F-FDG) positron emission tomography (PET) and PET/CT have become two of the most powerful tools for malignant lymphoma exploration, but their diagnostic role in primary central nervous system lymphoma (PCNSL) is still disputed. The purpose of our study is to identify the usefulness of 18 F-FDG PET and PET/CT for detecting PCNSL. Results: A total of 129 patients, obtained from eight eligible studies, were included for this systematic review and meta-analysis. The performance of 18 F-FDG PET and PET/CT for diagnosing PCNSL were as follows: the pooled sensitivity was 0.88 (95% CI: 0.80–0.94), specificity was 0.86 (95% CI: 0.73–0.94), positive likelihood ratio (PLR) was 3.99 (95% CI: 2.31–6.90), negative likelihood ratio (NLR) was 0.11 (95% CI: 0.04-0.32), and diagnostic odds ratio (DOR) was 33.40 (95% CI: 10.40–107.3). In addition, the area under the curve (AUC) and Q index were 0.9192 and 0.8525, respectively. Materials and Methods: PubMed/MEDLINE, Embase and Cochrane Library were systematically searched for potential publications (last updated on July 16th, 2016). Reference lists of included articles were also checked. Original articles that reported data on patients who were suspected of having PCNSL were considered suitable for inclusion. The sensitivities and specificities of 18 F-FDG PET and PET/CT in each study were evaluated. The Stata software and Meta-Disc software were employed in the process of data analysis. Conclusions: 18 F-FDG PET and PET/CT showed considerable accuracy in identifying PCNSL in immunocompetent patients and could be a valuable radiological diagnostic tool for PCNSL.
Zou et al. (Thu,) studied this question.